Premium
Pharmacology, Clinical Efficacy, and Safety of Drotrecogin alfa (activated)
Author(s) -
Rudis Maria I.,
Fish Douglas N.
Publication year - 2002
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.22.18.182s.33704
Subject(s) - drotrecogin alfa , protein c , medicine , sepsis , hemostasis , placebo , coagulation , pharmacology , disseminated intravascular coagulation , intensive care medicine , immunology , severe sepsis , septic shock , pathology , alternative medicine
The protein C pathway, which plays an important role in maintaining normal hemostasis and is a critical link between the inflammatory and procoagulant host responses to infection, is involved in modulating the coagulation and inflammation associated with severe sepsis. Recombinant human activated protein C (APC), or drotrecogin alfa (activated), shares the intrinsic pharmacologic activity of endogenous APC. In the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial, drotrecogin alfa (activated) decreased absolute mortality by 6% and relative risk of mortality by 19% compared with placebo. Drotrecogin alfa (activated) is an important advancement in the treatment of adult patients with severe sepsis.